2020
A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311
Ferris RL, Flamand Y, Holsinger FC, Weinstein GS, Quon H, Mehra R, Garcia JJ, Hinni ML, Gross ND, Sturgis EM, Duvvuri U, Méndez E, Ridge JA, Magnuson JS, Higgins KA, Patel MR, Smith RB, Karakla DW, Kupferman ME, Malone JP, Judson BL, Richmon J, Boyle JO, Bayon R, O'Malley BW, Ozer E, Thomas GR, Koch WM, Bell RB, Saba NF, Li S, Sigurdson ER, Burtness B. A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. Oral Oncology 2020, 110: 104797. PMID: 32679405, PMCID: PMC7771718, DOI: 10.1016/j.oraloncology.2020.104797.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedFemaleHumansMiddle AgedOropharyngeal NeoplasmsProspective StudiesQuality Assurance, Health CareRobotic Surgical ProceduresSurgeonsConceptsOropharyngeal cancerTransoral surgeryOropharyngeal bleedingPositive marginsTransoral resectionGrade III/IVSurgical oncology trialsPost-operative therapySurgical quality assuranceSurgical pathology reportsFinal pathologic marginsMulti-institutional dataPathologic marginsBleeding rateClinical trialsPathology reportsLower incidenceOngoing quality assuranceOncology trialsSurgical expertiseMeticulous evaluationSurgeon expertiseTransoral headPatientsSurgery
2019
Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201.
Iqbal S, McDonough S, Lenz HJ, Ilson D, Burtness B, Nangia CS, Barzi A, Schneider CJ, Liu JJ, Dotan E, Guthrie KA, Hochster HS. Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. Journal Of Clinical Oncology 2019, 38: 472-479. PMID: 31815582, PMCID: PMC7007287, DOI: 10.1200/jco.19.00925.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDNA-Binding ProteinsEndonucleasesEsophageal NeoplasmsEsophagogastric JunctionFemaleFluorouracilGene ExpressionHumansLeucovorinMaleMiddle AgedNeoplasm MetastasisOrganoplatinum CompoundsOxaliplatinPrognosisProgression-Free SurvivalProportional Hazards ModelsProspective StudiesStomach NeoplasmsYoung AdultConceptsProgression-free survivalAdvanced esophagogastric cancerPhase II studyPlatinum-based therapyOverall survivalII studySuperior median progression-free survivalMedian progression-free survivalMRNA expressionRegimen of irinotecanUpper GI tumorsZubrod performance statusPercent of patientsOccurrence of gradeStandard of careMetastatic esophagealEsophagogastric cancerPerformance statusUntreated patientsGastroesophageal cancerGI tumorsTreatment armsFOLFOXPlatinum sensitivityPatients
2018
Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer
Kelly JR, Park HS, An Y, Yarbrough WG, Contessa JN, Decker R, Mehra S, Judson BL, Burtness B, Husain Z. Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer. Oral Oncology 2018, 79: 64-70. PMID: 29598952, DOI: 10.1016/j.oraloncology.2018.02.017.Peer-Reviewed Original ResearchConceptsNational Cancer DatabasePrimary surgeryOverall survivalAdjuvant chemoradiotherapyDefinitive chemoradiotherapyUpfront surgerySurgical patientsHuman papillomavirus-associated oropharyngeal squamous cell carcinomaOropharyngeal squamous cell carcinomaPropensity score-matched analysisOropharyngeal squamous cell cancerCox proportional hazards regressionMultivariable Cox regressionNon-private insuranceInferior overall survivalMargin-negative resectionSquamous cell cancerProportional hazards regressionSquamous cell carcinomaLog-rank testChi-square testClinicopathologic predictorsSimilar OSSurgery patientsTrimodal therapy
2013
Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer
Lango MN, Egleston B, Fang C, Burtness B, Galloway T, Liu J, Mehra R, Ebersole B, Moran K, Ridge JA. Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. Cancer 2013, 120: 840-847. PMID: 24352973, PMCID: PMC3951722, DOI: 10.1002/cncr.28482.Peer-Reviewed Original ResearchConceptsDisease-related deathPatient-reported health stateDisease recurrenceBaseline dysphagiaWeight lossNeck cancerHealth perceptionPatient-reported dysphagiaECOG performance statusAdvanced T classificationProspective cohort studyGeneral health perceptionRisk of deathNeck cancer patientsPatient-reported measuresLogistic regression analysisHealth statesCurative intentDysphagia measuresCohort studyIdentifies patientsPerformance statusEuroQol-5DMale patientsSWAL-QOL
2000
Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial
Yanovich S, Mitsky P, Cornetta K, Maziarz R, Rosenfeld C, Krause D, Lotz J, Bitran J, Williams S, Preti R, Somlo G, Burtness B, Mills B. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplantation 2000, 25: 1165-1174. PMID: 10849529, DOI: 10.1038/sj.bmt.1702415.Peer-Reviewed Original ResearchConceptsHigh-risk breast cancer patientsBreast cancer patientsMedian timeCancer patientsIsolated CD34Clinical trialsCell selection systemHematopoietic reconstitutionHigh-risk breast cancerCapacity of CD34Transplantation of CD34Absolute neutrophil countDuration of hospitalizationHigh-dose chemotherapyMulticenter clinical trialBone Marrow Transplantation (2000) 25Incidence of infectionPeripheral blood cellsInter-group differencesProgenitor cell graftsPlatelet engraftmentNeutrophil countCell transplantPlatelet transfusionsPlatelet count
1998
High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study
Chabannon C, Cornetta K, Lotz J, Rosenfeld C, Shlomchik M, Yanovitch S, Marolleau J, Sledge G, Novakovitch G, Srour E, Burtness B, Camerlo J, Gravis G, Lee-Fischer J, Faucher C, Chabbert I, Krause D, Maraninchi D, Mills B, Kunkel L, Oldham F, Blaise D, Viens P. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. British Journal Of Cancer 1998, 78: 913-921. PMID: 9764583, PMCID: PMC2063121, DOI: 10.1038/bjc.1998.601.Peer-Reviewed Original ResearchConceptsPoor prognosis breast cancerHigh-dose chemotherapyHaematopoietic recoveryBreast cancerRecombinant human granulocyte colony-stimulating factorBlood cellsRandomized multicentre studyGranulocyte colony-stimulating factorHuman granulocyte colony-stimulating factorPeripheral blood cellsPeripheral blood CD34Peripheral blood progenitorsColony-stimulating factorMobilized blood cellsEpithelial tumor cellsEligible patientsStudy armsMulticentre studyPeripheral bloodConventional chemotherapyStudy groupPatientsChemotherapyBlood CD34CD34